Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.

Autor: van der Straten L; a Department of Internal Medicine , Albert Schweitzer Hospital , Dordrecht , The Netherlands., Dinmohamed AG; b Department of Research , Netherlands Comprehensive Cancer Organisation (IKNL) , Utrecht , The Netherlands.; c Department of Public Health , Erasmus University Medical Centre , Rotterdam , The Netherlands.; d Department of Hematology , Erasmus MC Cancer Institute , Rotterdam , The Netherlands., Westerweel PE; a Department of Internal Medicine , Albert Schweitzer Hospital , Dordrecht , The Netherlands., Langerak AW; e Department of Immunology , Erasmus University Medical Centre , Rotterdam , The Netherlands., Riedl J; f Department of Clinical Chemistry , Result laboratories, Albert Schweitzer Hospital , Dordrecht , The Netherland., Doorduijn JK; d Department of Hematology , Erasmus MC Cancer Institute , Rotterdam , The Netherlands., Kater AP; g Department of Hematology , Academic Medical Centre , Amsterdam , the Netherlands., Levin MD; a Department of Internal Medicine , Albert Schweitzer Hospital , Dordrecht , The Netherlands.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2018 Nov; Vol. 59 (11), pp. 2757-2761. Date of Electronic Publication: 2018 Apr 04.
DOI: 10.1080/10428194.2018.1452215
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje